Creative Touch Permanent Makeup and Aesthetics

The gut-skin axis describes the bidirectional biological relationship between gut microbiome composition and skin health – mediated through at least four overlapping mechanisms: circulating inflammatory mediators from gut dysbiosis, short-chain fatty acid (SCFA) depletion impairing skin immune tolerance, stress-driven gut permeability changes amplifying systemic inflammation, and autoimmune cross-reactivity from leaky gut peptide translocation. In its fuller form – the brain-gut-skin axis – the hypothalamic-pituitary-adrenal (HPA) stress response forms a third arm, connecting psychological and physiological stress directly to both gut permeability and skin barrier impairment simultaneously. Mendelian randomisation studies now provide the closest epidemiological evidence for causation – rather than mere association – between gut microbiome composition and specific inflammatory skin conditions including atopic dermatitis, psoriasis, rosacea, and acne. The gut-skin axis is not a single pathway but a convergence of immune, metabolic, neuroendocrine, and barrier function mechanisms, each with distinct therapeutic implications and each relevant to the mechanistic understanding of why dietary pattern, stress management, and metabolic health are legitimate determinants of skin condition.

Skin conditions are frequently managed as if they are isolated dermatological events – responsive to topical treatment, laser intervention, or systemic medication targeting the skin directly. The gut-skin axis challenges this framing at a mechanistic level: it describes a system in which the state of the gut microbiome, the integrity of the gut epithelial barrier, and the hormonal output of the stress response all have measurable, causal consequences for skin inflammation, barrier function, and immune regulation. Understanding the axis does not replace dermatological management – it contextualises why the same treatment produces different outcomes in different patients, and why metabolic and dietary variables are relevant to skin health in ways that go beyond simple nutrition.

The Shared Barrier Principle

Gut epithelial barrier and skin barrier are not anatomically connected but share a fundamental biological architecture. Both are maintained by tight junction protein complexes – claudins, occludins, and zonula occludens proteins – that regulate paracellular permeability and prevent inappropriate passage of microorganisms, toxins, and inflammatory triggers across the barrier surface. Both are regulated by similar cytokine environments: IL-4, IL-13, and IL-33 (Th2 cytokines) impair tight junction integrity in both gut epithelium and skin keratinocytes; IL-22 supports barrier repair in both tissues. Both are colonised by microbiome communities – gut and skin microbiomes are anatomically separate but immunologically communicating, with gut-derived immune signals shaping skin immune tone through circulating cells and mediators. ^[1]

The practical implication is that disruption of one barrier is associated with disruption of the other – not through direct anatomical connection but through shared regulatory mechanisms. The atopic march – the progression from infant gut dysbiosis to eczema to allergic rhinitis to asthma – is the most clinically documented expression of this shared regulation, with impaired gut barrier programming in early life predicting impaired skin barrier development. ^[2]

Pathway 1: LPS, Metabolic Endotoxaemia, and Skin Inflammation

Gut dysbiosis – driven by high sugar and UPF intake, antibiotic exposure, or chronic stress – reduces the abundance of commensal bacteria and increases the relative proportion of gram-negative species whose outer membranes contain lipopolysaccharide (LPS). Increased intestinal permeability allows LPS to translocate into portal and then systemic circulation – a state of metabolic endotoxaemia. ^[6]

Circulating LPS activates Toll-like receptor 4 (TLR4) on immune cells, keratinocytes, and sebaceous gland cells in skin, triggering NF-κB-mediated upregulation of IL-1β, IL-6, TNF-α, and IL-17. The LPS/TLR4/NF-κB mechanism is the same inflammatory cascade that drives insulin resistance in T2DM – in skin, it drives sebaceous inflammation in acne, sustains the Th17/IL-17/IL-23 axis activation in psoriasis, and contributes to the neurogenic inflammation and vascular dysregulation of rosacea. The dietary upstream of this pathway – the LPS-generating role of UPF and high-sugar dietary patterns – is developed in the High Sugar and UPF Intake entity; this entity focuses on the skin-specific downstream consequences.

Pathway 2: Protective Microbiome Metabolites – SCFAs, Tregs, and Gut Barrier Integrity

The anti-inflammatory arm of the gut-skin axis is less well-known than the LPS pathway but is mechanistically equally important. Commensal bacteria – particularly Bifidobacterium, Lactobacillus, Faecalibacterium prausnitzii, and Roseburia species – ferment dietary fibre to produce short-chain fatty acids: principally butyrate, propionate, and acetate. ^[5]

SCFAs regulate skin immune function through two converging mechanisms:

Systemic immune regulation: SCFAs absorbed from the colon enter portal circulation and promote the differentiation of regulatory T cells (Tregs) in gut-associated lymphoid tissue (GALT) via HDAC inhibition – particularly by butyrate, which suppresses histone deacetylase activity and upregulates Foxp3 expression, the master transcription factor for Treg identity. These Tregs are not gut-confined: they migrate systemically, including to skin, where Foxp3 expression has been confirmed in skin-homing Tregs. Tregs in skin actively suppress excessive Th2 and Th17 responses – the immune phenotypes that drive atopic dermatitis and psoriasis respectively. SCFA depletion, as occurs in gut dysbiosis, removes this active suppression and shifts the skin immune environment towards pro-inflammatory states. ^[4]

Direct keratinocyte signalling: Keratinocytes express free fatty acid receptors FFAR2 and FFAR3, which respond to SCFAs – particularly propionate – to promote epigenetic changes in gene expression related to barrier function, keratinocyte differentiation, and local immune regulation. SCFAs reaching skin through systemic circulation can therefore directly modulate keratinocyte behaviour independently of their immune regulatory effects. ^[8] SCFA production modulation represents a mechanistic link between obesity-associated gut dysbiosis, GLP-1 RA treatment, and atopic dermatitis outcomes – GLP-1 RAs modulate gut microbiota composition in ways that enhance SCFA-producing bacterial abundance, specifically increasing Roseburia and F. prausnitzii in both human and animal investigations. ^[3]

A structurally distinct but complementary gut barrier protection mechanism operates via indole-3-propionic acid (IPA) – a metabolite produced exclusively by commensal gut bacteria, principally Clostridium sporogenes, through the bacterial catabolism of dietary tryptophan. Unlike SCFAs, which are produced by fermentation of dietary fibre, IPA derives from an amino acid substrate and acts via a separate receptor pathway: IPA binds the pregnane X receptor (PXR) on intestinal epithelial cells, upregulating tight junction proteins including claudin-1 and occludin, and reducing intestinal permeability independently of the SCFA/butyrate pathway. IPA also functions as a direct antioxidant, scavenging reactive oxygen species within the gut epithelium and reducing oxidative barrier stress. Because IPA is produced exclusively by gut bacteria – it cannot be synthesised endogenously – its blood concentration serves as a direct functional marker of commensal microbiome activity and gut barrier competency; dysbiosis that reduces commensal abundance therefore suppresses IPA production and withdraws this protective mechanism simultaneously. The functional balance between IPA and kynurenine – an alternative tryptophan metabolite produced via the inflammation-driven kynurenine pathway when IDO is upregulated by LPS and IFN-γ – provides an accessible blood-based readout of the competing states of gut protection versus gut immune activation; this tryptophan metabolite balance is developed further in the Gut Microbiome entity.

Pathway 3: The Stress Arm – HPA Axis, Gut Permeability, and Skin

The brain-gut-skin axis framing adds a third signalling direction to the bilateral gut-skin relationship: brain → gut → skin, mediated by the HPA stress response. ^[9]

Psychological and physiological stress activates the hypothalamus to release corticotropin-releasing hormone (CRH), which triggers cortisol release via the pituitary-adrenal axis. Critically, CRH also acts directly on intestinal mast cells – which express CRH receptors – to destabilise gut tight junctions and increase intestinal permeability. A 2014 Gut (BMJ) clinical study in healthy human volunteers demonstrated this mechanism directly: acute psychological stress increased small intestinal permeability as measured by lactulose-mannitol ratio; peripheral CRH administration reproduced the effect; and pretreatment with the mast cell stabiliser disodium cromoglycate (DSCG) blocked both the stress-induced and CRH-induced permeability increases – confirming mast cell involvement as the required intermediate step. ^[9]

The skin consequences operate through two parallel routes. Increased intestinal permeability from stress-driven CRH/mast cell activation allows greater LPS translocation, amplifying the systemic inflammatory load that drives skin inflammation. Simultaneously, elevated cortisol directly impairs skin barrier function by downregulating filaggrin expression – the structural protein essential to the stratum corneum’s water-retention capacity and barrier integrity – and by suppressing keratinocyte proliferation and tight junction protein expression. The stress arm therefore hits both gut and skin simultaneously and convergently, producing a compounding inflammatory and barrier-impairing effect that exceeds what either route would generate alone.

Pathway 4: Leaky Gut and Autoimmune Skin Triggers

Increased intestinal permeability allows not only LPS but partially digested food-derived peptides and microbial antigens to enter systemic circulation. In genetically predisposed individuals, these circulating antigens can trigger or amplify autoimmune responses through molecular mimicry – the structural similarity between microbial or dietary peptides and self-proteins that causes immune responses targeting the foreign antigen to cross-react with host tissue. ^[1]

The relevance to autoimmune skin conditions is direct. Vitiligo – autoimmune destruction of epidermal melanocytes – shows documented association with gut dysbiosis and altered microbiome composition, with the autoimmune cross-reactivity hypothesis providing a plausible mechanistic explanation for the gut-skin connection. Alopecia areata – autoimmune follicular attack – shows similar associations. In both conditions, the gut-skin axis is likely one of several upstream contributors rather than a sole cause; the mechanistic plausibility is strong, and the clinical co-occurrence of these conditions with inflammatory bowel disease – itself a gut barrier dysfunction condition – is consistent with the shared barrier/autoimmune axis hypothesis. ^[1]

Skin Condition Evidence

Atopic dermatitis (eczema): The strongest gut-skin axis evidence base. Reduced microbiome diversity in early infancy – particularly Bifidobacterium depletion – predicts atopic dermatitis development through impaired Th2 immune regulation and reduced SCFA-mediated barrier programming. Mendelian randomisation studies confirm causal rather than merely associative relationships between gut microbiome composition and atopic dermatitis risk. The SCFA/Treg/Foxp3 pathway is the primary anti-inflammatory mechanism whose loss predicts disease. ^[11]

Psoriasis: Reduced abundance of Faecalibacterium prausnitzii – a major butyrate producer – correlates with psoriasis severity across multiple cohort studies. Mendelian randomisation evidence for gut microbiome → psoriasis causation is now available. The gut-skin connection operates primarily through SCFA depletion → loss of Treg suppression → unopposed Th17/IL-23/IL-17 axis activation – the same immune axis that psoriasis biologics target pharmacologically. ^[12]

Rosacea and SIBO: The rosacea/gut connection is one of the most clinically striking in the entire gut-skin axis literature. Small intestinal bacterial overgrowth (SIBO) prevalence is significantly higher in rosacea patients than controls. A controlled clinical study found that rifaximin-mediated SIBO eradication produced complete or near-complete rosacea lesion clearance in 78% of successfully treated patients, maintained for at least nine months without further treatment – compared to no improvement or worsening in the placebo group. The mechanism is presumed to involve SIBO-generated LPS and bacterial metabolites driving systemic and cutaneous vascular inflammation; the near-complete and durable skin response to gut treatment alone is one of the strongest therapeutic demonstrations of the gut-skin axis in clinical practice. ^[10]

Acne: Gut dysbiosis → LPS → TLR4 activation in sebaceous glands → IL-1β-driven follicular inflammation; SCFA depletion → loss of regulatory T cell suppression of Cutibacterium acnes inflammatory response. The acne/gut connection is mechanistically coherent and supported by the observation that high-glycaemic dietary patterns – which drive dysbiosis – worsen acne, whilst fibre-rich dietary patterns improve it. ^[6]

Vitiligo and alopecia areata: Autoimmune skin conditions with documented gut microbiome associations and plausible leaky gut → autoimmune cross-reactivity mechanisms. Evidence is less mature than for AD and psoriasis; the associations are consistent but causal Mendelian randomisation data are less developed. ^[1]

Therapeutic Implications

The gut-skin axis evidence base does not support specific treatment claims. What it does support is the mechanistic framing of dietary pattern and stress management as legitimate, evidence-grounded contributors to skin health outcomes, not merely lifestyle recommendations layered onto dermatological management.

The dietary implications are specific rather than generic: dietary fibre supports SCFA-producing bacterial abundance and the Treg/Foxp3/skin immune tolerance pathway; fermented foods support commensal bacterial diversity; reduction in high-sugar and UPF intake reduces the LPS-generating dysbiosis that drives cutaneous TLR4/NF-κB inflammation. Probiotic supplementation has shown benefit in atopic dermatitis in some RCTs – particularly Lactobacillus rhamnosus GG in infant populations – but the evidence for specific strains in adult skin conditions remains inconsistent and is not sufficient to make treatment claims. ^[7]

For clients presenting with inflammatory skin conditions at Creative Touch, the gut-skin axis provides a credible mechanistic framework for discussing how dietary pattern, stress management, and metabolic health interact with skin biology – and for signposting relevant dietary or lifestyle changes as adjuncts to, rather than replacements for, dermatological treatment. It also frames the gut microbiome as a legitimate variable in treatment responsiveness – a client with significant dysbiosis may have a chronically elevated skin inflammatory baseline that limits response to anti-inflammatory aesthetic treatments regardless of the treatment’s own efficacy.